The US Agency for International Development has announced a $100.0 million award to the nonprofit research organization RTI International to reduce the impact of neglected tropical diseases in developing nations.
The project, which will treat more than 40 million people over five years, represents one of the first large-scale efforts to integrate existing disease-specific treatment programs to care for millions of the world's poorest people. The project will build on the success of those programs, bringing them to national scale and enhancing their effectiveness and efficiency by integrating treatment, monitoring and evaluation programs, according to the USAID.
"This significant investment will improve the lives of millions of people afflicted with disabling conditions through effective, low-cost, mass drug administration and associated education programs," said Richard Greene, director of the Office of Health, Infectious Disease and Nutrition at the USAID.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze